Related references
Note: Only part of the references are listed.CD47/SIRPα axis: bridging innate and adaptive immunity
Anneloes van Duijn et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
Robert W. Lentz et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Role of Mammalian DNA Methyltransferases in Development
Zhiyuan Chen et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 89 (2020)
Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers
Sung-Yup Cho et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng et al.
NATURE REVIEWS CANCER (2019)
The MYC oncogene is a global regulator of the immune response
Stephanie C. Casey et al.
BLOOD (2018)
DNA methylation-based classification of central nervous system tumours
David Capper et al.
NATURE (2018)
Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
Tobias Goschzik et al.
LANCET ONCOLOGY (2018)
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study
Edward C. Schwalbe et al.
LANCET ONCOLOGY (2017)
The whole-genome landscape of medulloblastoma subtypes
Paul A. Northcott et al.
NATURE (2017)
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
Sharareh Gholamin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Florence M. G. Cavalli et al.
CANCER CELL (2017)
Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma
Bree R. Eaton et al.
NEURO-ONCOLOGY (2016)
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
Vijay Ramaswamy et al.
ACTA NEUROPATHOLOGICA (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma
Yanxin Pei et al.
CANCER CELL (2016)
TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy
Han Zhang et al.
CANCER RESEARCH (2016)
Divergent clonal selection dominates medulloblastoma at recurrence
A. Sorana Morrissy et al.
NATURE (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
Michael Zhang et al.
PLOS ONE (2016)
BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells
Iwona Anna Ciechomska et al.
SCIENTIFIC REPORTS (2016)
Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease
Rebecca M. Hill et al.
CANCER CELL (2015)
Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk
Mingye Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Jonas Ecker et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma
Marie Morfouace et al.
CANCER CELL (2014)
Cytogenetic Prognostication Within Medulloblastoma Subgroups
David J. H. Shih et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Processing Speed, Attention, and Working Memory After Treatment for Medulloblastoma: An International, Prospective, and Longitudinal Study
Shawna L. Palmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis
Vijay Ramaswamy et al.
LANCET ONCOLOGY (2013)
Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961
Roger J. Packer et al.
NEURO-ONCOLOGY (2013)
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma
Andrey Korshunov et al.
ACTA NEUROPATHOLOGICA (2012)
Molecular subgroups of medulloblastoma: the current consensus
Michael D. Taylor et al.
ACTA NEUROPATHOLOGICA (2012)
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
Marcel Kool et al.
ACTA NEUROPATHOLOGICA (2012)
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
Mark P. Chao et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment
Till Milde et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Programmed cell removal: a new obstacle in the road to developing cancer
Mark P. Chao et al.
NATURE REVIEWS CANCER (2012)
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Mark P. Chao et al.
CANCER RESEARCH (2011)
FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma
Marc Remke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome
Yoon-Jae Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Monoclonal antibodies in neuro-oncology Getting past the blood-brain barrier
Lois A. Lampson
MABS (2011)
Epigenetic Changes in Cancer
Christine A. Iacobuzio-Donahue
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts
Lalji K. Gediya et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
CNS immune privilege: hiding in plain sight
Monica J. Carson et al.
IMMUNOLOGICAL REVIEWS (2006)
Neurocognitive consequences of risk-adapted therapy for childhood medulloblastorna
RK Mulhern et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis
RS Klein et al.
JOURNAL OF IMMUNOLOGY (2004)
Regulation of neuroinflammation: The role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis
RS Klein
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Share Paper
